
|Articles|April 14, 2017
- Vol 34 No 4
- Volume 34
- Issue 4
Taking the Pulse
Author(s)Richard M. Berlin, MD
Introduce yourself, shake hands, sit down. Always sit down. Then ask for permission...
Advertisement
Introduce yourself,
shake hands, sit down.
Always sit down.
Then ask for permission.
Press the wrist’s flesh
with the same pressure
you placed on your chest
when you swore your oath.
Count the rate.
Close your eyes.
Appreciate the rhythm,
each rise and fall,
crescendo, pause,
flutter and thrill,
the flow, the stream,
a body entered
through 2 fingertips
with enough nerve
and sense to reveal
the secrets deep
in your patient’s heart.
Articles in this issue
over 9 years ago
Introduction: Deep Dives and Intellectual Jujitsuover 9 years ago
Assisted Outpatient Treatment Enters the Mainstreamover 9 years ago
Across the (Psychiatric) Universeover 9 years ago
Bizarro WorldAdvertisement
Related to this article

Learn how IPV shapes mental health from pregnancy to adulthood, and how clinicians assess risk, plan safety, and treat victims and perpetrators.

Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.

Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.

A case report and review of 13 similar cases suggest that late-onset clozapine neutropenia may sometimes reflect neutrophil margination rather than marrow suppression, with corticosteroids, granulocyte colony-stimulating factor, or lithium as possible, carefully monitored paths to continuing treatment.

Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.

Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.

Atypical psychedelics such as ketamine, MDMA, and ibogaine show fast-acting promise for depression, PTSD, and addiction beyond 5-HT2A.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
3
New Analyses of HLP003 for the Adjunctive Treatment of MDD
4
New Real-World Data Supporting Cariprazine for MDD and Bipolar I Depression
5

